Immuno-oncology Therapy Market by Therapy Type and by Therapeutic Areas, for Hospitals, Clinics and Cancer Research Institutes: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

  • ID: 4531873
  • Report
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 3
The report covers forecast and analysis for the immuno-oncology therapy market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the immuno-oncology therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the immuno-oncology therapy market on a global level.

In order to give the users of this report a comprehensive view of the immuno-oncology therapy market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein therapy type segment, therapeutic area segment, and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.

The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others. Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Key end-users covered under this study include hospitals, clinics, ASCs and cancer research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East Africa with its further bifurcation into major countries including the U.S., Canada, Rest of North America, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Qatar, South Africa and Rest of Middle East and Africa. This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.

The report also includes detailed profiles of end players such as Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc. and Takeda Pharmaceuticals.

This report segments the global immuno-oncology therapy market as follows:

Global Immuno-oncology Therapy Market: Therapy Type Segment Analysis:
Monoclonal Antibodies
Immune Checkpoint Inhibitors
PD-1/ PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Others

Global Immuno-oncology Therapy Market: Therapeutic Area Segment Analysis:
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Others Cancers

Global Immuno-oncology Therapy Market: End-user Segment Analysis:
Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)
Cancer Research Institutes

Global Immuno-oncology Therapy Market: Regional Segment Analysis:
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology

2. Executive Summary
2.1. Global Immuno-oncology Therapy Market, 2016 2022 (USD Billion)
2.2. Global Immuno-oncology Therapy Market: Snapshot

3. Immuno-oncology Therapy Market Market Dynamics
3.1. Introduction
3.2. Market Drivers
3.2.1. Global immuno-oncology therapy market drivers: Impact analysis
3.2.2. Highly Promising Treatment Pipeline
3.2.3. Increase in Number of Patients Suffering from Various Cancers
3.2.4. Greater Efficiency Over Conventional Treatment Methods
3.3. Market Restraints
3.3.1. Global immuno-oncology therapy market restraints: Impact analysis
3.3.2. High Level of Attrition within the Development Cycles
3.3.3. Stringent Regulatory Framework
3.3.4. Lack of Awareness of Immunotherapy
3.4. Opportunities
3.4.1. Developed Economies Showing Higher Development Rates
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by therapy type segment
3.6.2. Market attractiveness analysis, by end-user segment
3.6.3. Market attractiveness analysis, by regional segment

4. Global Immuno-oncology Therapy Market Competitive Landscape
4.1. Company Market Share Analysis
4.1.1. Global immuno-oncology therapy market: company market share, 2016
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Therapy Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development and Regional Expansion
4.3. Price Trend Analysis

5. Global Immuno-oncology Therapy Market Therapy Type Segment Analysis
5.1. Global immuno-oncology therapy market: therapy type overview
5.1.1. Global immuno-oncology therapy market revenue share, by therapy type, 2016 and 2022
5.2. Monoclonal Antibodies
5.2.1. Global immuno-oncology therapy market for monoclonal antibodies market, 2016 2022 (USD Billion)
5.3. Immune Checkpoint Inhibitors
5.3.1. Global immuno-oncology therapy market for immune checkpoint inhibitors market, 2016 2022 (USD Billion)
5.3.1.1. Global immuno-oncology therapy market for PD1/ PDL1 market, 2016 2022 (USD Billion)
5.3.1.2. Global immuno-oncology therapy market for CTLA-4 market, 2016 2022 (USD Billion)
5.4. Immune System Modulators
5.4.1. Global immuno-oncology therapy market for immune system modulators market, 2016 2022 (USD Billion)
5.5. Cancer Vaccines
5.5.1. Global immuno-oncology therapy market for cancer vaccines market, 2016 2022 (USD Billion)
5.6. Others
5.6.1. Global immuno-oncology therapy market for others market, 2016 2022 (USD Billion)

6. Global Immuno-oncology Therapy Market Therapeutic Area Segment Analysis
6.1. Global immuno-oncology therapy market: therapeutic area overview
6.1.1. Global immuno-oncology therapy market revenue share, by therapeutic area, 2016 and 2022
6.2. Lung Cancer
6.2.1. Global immuno-oncology therapy market for lung cancer market, 2016 2022 (USD Billion)
6.3. Colorectal Cancer
6.3.1. Global immuno-oncology therapy market for colorectal cancer market, 2016 2022 (USD Billion)
6.4. Breast Cancer
6.4.1. Global immuno-oncology therapy market for breast cancer market, 2016 2022 (USD Billion)
6.5. Prostate Cancer
6.5.1. Global immuno-oncology therapy market for prostate cancer market, 2016 2022 (USD Billion)
6.6. Melanoma
6.6.1. Global immuno-oncology therapy market for melanoma market, 2016 2022 (USD Billion)
6.7. Blood Cancer
6.7.1. Global immuno-oncology therapy market for blood cancer market, 2016 2022 (USD Billion)
6.8. Other Cancers
6.8.1. Global immuno-oncology therapy market for other cancers market, 2016 2022 (USD Billion)

7. Global Immuno-oncology Therapy Market End-User Segment Analysis
7.1. Global immuno-oncology therapy market: end-user overview
7.1.1. Global immuno-oncology therapy market revenue share, by end-user, 2016 and 2022
7.2. Hospitals
7.2.1. Global immuno-oncology therapy market for hospitals 2016 2022 (USD Billion)
7.3. Clinics
7.3.1. Global immuno-oncology therapy market for clinics, 2016 2022 (USD Billion)
7.4. Ambulatory Surgical Centers (ASCs)
7.4.1. Global immuno-oncology therapy market for ambulatory surgical centers, 2016 2022 (USD Billion)
7.5. Cancer Research Institutes
7.5.1. Global immuno-oncology therapy market for cancer research institutes end-users, 2016 2022 (USD Billion)

8. Global Immuno-oncology Therapy Market Regional Segment Analysis
8.1. Global immuno-oncology therapy market: regional overview
8.1.1. Global immuno-oncology therapy market revenue share, by region, 2016 and 2022
8.2. North America
8.2.1. North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.2.2. North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.2.3. North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.2.4. U.S.
8.2.4.1. U.S. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.2.4.2. U.S. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.2.4.3. U.S. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.2.5. Canada
8.2.5.1. Canada immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.2.5.2. Canada immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.2.5.3. Canada immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.2.6. Rest of North America
8.2.6.1. Rest of North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.2.6.2. Rest of North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.2.6.3. Rest of North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3. Europe
8.3.1. Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.2. Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.3. Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.4. U.K.
8.3.4.1. U.K. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.4.2. U.K. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.4.3. U.K. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.5. Germany
8.3.5.1. Germany immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.5.2. Germany immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.5.3. Germany immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.6. France
8.3.6.1. France immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.6.2. France immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.6.3. France immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.7. Italy
8.3.7.1. Italy immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.7.2. Italy immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.7.3. Italy immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.8. Spain
8.3.8.1. Spain immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.8.2. Spain immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.8.3. Spain immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.9. Russia
8.3.9.1. Russia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.9.2. Russia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.9.3. Russia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.3.10. Rest of Europe
8.3.10.1. Rest of Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.3.10.2. Rest of Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.3.10.3. Rest of Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.4.2. Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.3. Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4.4. China
8.4.4.1. China immuno-oncology therapy market revenue, by therapy type, 2016 2022(USD Billion)
8.4.4.2. China immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.4.3. China immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4.5. Japan
8.4.5.1. Japan immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.4.5.2. Japan immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.5.3. Japan immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4.6. India
8.4.6.1. India immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.4.6.2. India immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.6.3. India immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4.7. Australia
8.4.7.1. Australia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.4.7.2. Australia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.7.3. Australia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.4.8. Rest of Asia Pacific
8.4.8.1. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.4.8.2. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.4.8.3. Rest of Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.5. Latin America
8.5.1. Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.5.2. Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.5.3. Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.5.4. Brazil
8.5.4.1. Brazil immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.5.4.2. Brazil immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.5.4.3. Brazil immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.5.5. Mexico
8.5.5.1. Mexico immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.5.5.2. Mexico immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.5.5.3. Mexico immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.5.6. Argentina
8.5.6.1. Argentina immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.5.6.2. Argentina immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.5.6.3. Argentina immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.5.7. Rest of Latin America
8.5.7.1. Rest of Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.5.7.2. Rest of Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.5.7.3. Rest of Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6. Middle East and Africa
8.6.1. Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.2. Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.3. Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6.4. Saudi Arabia
8.6.4.1. Saudi Arabia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.4.2. Saudi Arabia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.4.3. Saudi Arabia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6.5. UAE
8.6.5.1. UAE immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.5.2. UAE immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.5.3. UAE immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6.6. Qatar
8.6.6.1. Qatar immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.6.2. Qatar immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.6.3. Qatar immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6.7. South Africa
8.6.7.1. South Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.7.2. South Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.7.3. South Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
8.6.8. Rest of Middle East and Africa
8.6.8.1. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
8.6.8.2. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
8.6.8.3. Rest of Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

9. Company Profile
9.1. Amgen, Inc.
9.1.1. Overview
9.1.2. Financials
9.1.3. Therapy portfolio
9.1.4. Business strategy
9.1.5. Recent developments
9.2. AstraZeneca Plc.
9.2.1. Overview
9.2.2. Financials
9.2.3. Therapy portfolio
9.2.4. Business strategy
9.2.5. Recent developments
9.3. Bristol-Myers Squibb Company
9.3.1. Overview
9.3.2. Financials
9.3.3. Therapy portfolio
9.3.4. Business strategy
9.3.5. Recent developments
9.4. Eli Lilly and Company
9.4.1. Overview
9.4.2. Financials
9.4.3. Therapy portfolio
9.4.4. Business strategy
9.4.5. Recent developments
9.5. F.Hoffmann-La Roche Ltd.
9.5.1. Overview
9.5.2. Financials
9.5.3. Therapy portfolio
9.5.4. Business strategy
9.5.5. Recent developments
9.6. GlaxoSmithKline Plc.
9.6.1. Overview
9.6.2. Financials
9.6.3. Therapy portfolio
9.6.4. Business strategy
9.6.5. Recent developments
9.7. Janssen Biotech
9.7.1. Overview
9.7.2. Financials
9.7.3. Therapy portfolio
9.7.4. Business strategy
9.7.5. Recent developments
9.8. Merck and Co.
9.8.1. Overview
9.8.2. Financials
9.8.3. Therapy portfolio
9.8.4. Business strategy
9.8.5. Recent developments
9.9. Novartis AG
9.9.1. Overview
9.9.2. Financials
9.9.3. Therapy portfolio
9.9.4. Business strategy
9.9.5. Recent developments
9.10. Pfizer, Inc.
9.10.1. Overview
9.10.2. Financials
9.10.3. Therapy portfolio
9.10.4. Business strategy
9.10.5. Recent developments
9.11. Sanofi
9.11.1. Overview
9.11.2. Financials
9.11.3. Therapy portfolio
9.11.4. Business strategy
9.11.5. Recent developments
9.12. Spectrum Pharmaceuticals, Inc.
9.12.1. Overview
9.12.2. Financials
9.12.3. Therapy portfolio
9.12.4. Business strategy
9.12.5. Recent developments
9.13. Takeda Pharmaceuticals
9.13.1. Overview
9.13.2. Financials
9.13.3. Therapy portfolio
9.13.4. Business strategy
9.13.5. Recent developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll